Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors, Independent Investigator Study

NCT00802919 is registered in ClinicalTrials.gov with Nathan Kline Institute for Psychiatric Research as lead sponsor.

NCT NCT00802919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00802919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors, Independent Investigator Study
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2008
Completion date
December 31, 2013
Enrollment
93 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cigarette smoking, schizophrenia